Biden Administration Anticipated to Approve Psychedelic Therapies
Anticipated FDA approval of MDMA and psilocybin treatments outlined in recent Health and Human Services letter
With both mental health and drug misuse crises killing thousands of people per day around the globe, the potential benefits of psychedelic-assisted therapies “must be explored,” urges a federal letter from the Health and Human Services Department.
Biden’s administration anticipates that the FDA will approve both psilocybin and MDMA within the next 2 years for designated breakthrough therapies. Maladies topping the list include PTSD and depression – both of which have been shown to decrease with psilocybin and MDMA therapies.
The most promising takeaway from the letter is that the Biden administration is “exploring the prospect of establishing a federal task force to monitor the emerging psychedelic treatment ecosystem”.
This recent correspondence, not shared publicly until now, is the most promising indication to date that top officials are preparing for the approval of psychedelic drugs. Which was completely unthinkable even 5 years ago after the long fought Nixon War on Drugs as a means to attack the anti-Vietnam War counterculture in the late 1960s.
Biden Administration Anticipated to Approve Psychedelic Therapies
About Cannin Investment Group: Your Psychedelic Stocks Experts
Cannin is your trusted resource for psychedelic stocks. Our global team of experts evaluates all emerging psychedelic stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best psychedelic stock investments for 2021.
Use Cannin as your resource for:
Is it too late to invest in psychedelic stocks? No! This is the perfect time to invest.
Are you looking to buy stock in the best psychedelic companies for 2021? Interested in emerging penny psychedelic stocks? We can help.
Are you interested in psychedelic stocks like MindMed, Compass Pathways or Revive Therapeutics?
Predict price movements of stocks several hours in advance with our proprietary algorithmic stock trading software.
- +34% Gains in 2022
- +56% Gains in 2021
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best psychedelic stocks – we’ll show you how at cannin.com.
